AlleyCorp raises $335M second fund, bets early on unfashionable ideas

Kevin Ryan, known as "the Godfather of NYC Tech," has built a career on changing his mind when evidence demands it. His journey with psychedelics exemplifies this: skeptical until 2018, when he read Michael Pollan's How to Change Your Mind and encountered supporting data, he became a key backer of the Yale Center for Psychedelic Research and cofounded Transcend Therapeutics, a psychoactive drug maker that sold in June for $1.2 billion（約1900億円）. "What I think about is where the world's going five to ten years from now, and then we need to make a bet when it's not obvious," Ryan said. "If it's obvious, it's worth $20 billion（約3.2兆円） and it's too late."

AlleyCorp, the venture firm Ryan founded as a family office in 2007, has incubated dozens of companies including MongoDB, Business Insider, Gilt Groupe, and Zola. Previous investments have generated an all-time 60% IRR. In 2024, the firm took on outside investors for the first time with a $250 million（約400億円） fund. Now, AlleyCorp is announcing its $335 million（約540億円） second fund—a move Ryan says reflects the firm's commitment to early-stage bets rather than a shift in strategy. "We just invested last week in a company [at] a $25 million（約40億円） valuation, and they have $500,000 in revenue so far," Ryan said. "We need to help them build that business. That's what we do, and that's what we were doing six, seven years ago. The fundamentals haven't changed much."

AlleyCorp's current portfolio includes eight unicorns—Rogo, ShopMy, Valar Atomics, and Thyme Care among them—and the firm focuses on healthcare, deep tech, and general tech. Ryan is explicit about the difference between his approach and the mega-rounds reshaping venture capital. In 2026 so far, $412.7 billion（約66兆円） in U.S. venture dollars have been deployed into just a few companies, with tens of billions flowing into Anthropic and OpenAI. "I don't think that's venture capital," Ryan said. "Today, [DoubleClick] would have been private for ten years, and gone public at a $10 billion（約1.6兆円） valuation. If it's Anthropic, they wait until $1 trillion（約160兆円） and it's all 'VC money' but it's not—these are bigger than public companies." He suggests that when SpaceX, Anthropic, and OpenAI are removed from the tally, overall VC deployment may appear to have declined.

Ryan defines venture by check size and stage, not fund size, and says he remains devoted to first checks under $10 million（約16億円）. He is not opposed to raising a larger fund eventually. "Our next fund could be bigger—it could be 500, 600 [million]," he said. "You can expand in two ways without changing your strategy: One's verticals, another is geography. Say, if tomorrow, I had a $500 or $600 million（約960億円） fund, I'd consider having two biotech people and a biotech practice. But it doesn't change anything we do." The AlleyCorp Building in Manhattan's Nolita neighborhood opened in June and now houses a restaurant and several companies and VC firms, including Benchstrength and BBG Ventures.

Ryan reflects on the pace of change in tech, noting the gap between prediction and reality. "I was on some panel in 2017, where [everyone] would have sworn that by 2026, 50% of cars are going to be driverless," he said. "We're basically at 0% if you round up." Yet AI has moved with unprecedented speed. He cites Sebastian Mallaby's The Infinity Machine: Demis Hassabis, DeepMind and the Quest for Superintelligence, noting that the book, published roughly 12–18 months before the interview, does not mention Claude—now the dominant topic. "It's almost like your grandmother saying: 'Do you remember the Spanish-American War?' And you say: 'No, we don't really think about that anymore.' But we're talking about the world from 18 months ago."

AlleyCorp's $335 million（約540億円） second fund arrives in a venture landscape fundamentally reshaped by AI funding concentration. Ryan's framing is revealing: he notes that $412.7 billion（約66兆円） in U.S. venture dollars in 2026 so far has flowed into just a few companies, with tens of billions pouring into Anthropic and OpenAI. He explicitly argues these are no longer venture capital but a distinct asset class larger than public companies—a shift that redefines what "venture" means at scale. His earlier example of DoubleClick (which he sold for $1.1 billion（約1800億円） in 2005) illustrates the point: if founded today, it would remain private far longer and exit at a $10 billion（約1.6兆円） valuation, yet the mega-rounds into AI-first companies reach $1 trillion（約160兆円） and are still labeled "VC money."

This positions AlleyCorp's strategy as a deliberate counter-current. By doubling down on first checks under $10 million（約16億円） and early-stage bets where "it's not obvious," Ryan is betting that value creation will persist in overlooked areas. His psychedelics example—moving from skepticism to backing the Yale Center for Psychedical Research and cofounding Transcend Therapeutics, which sold for $1.2 billion（約1900億円） in June—demonstrates his willingness to shift conviction on contrarian theses when data emerges. The firm's portfolio of eight unicorns (Rogo, ShopMy, Valar Atomics, Thyme Care) suggests the approach has worked, even as mega-rounds dominate headlines.

Ryan's openness to expanding the fund to $500–600 million through vertical (biotech) or geographic expansion signals confidence in the model without changing stage focus—a disciplined growth path distinct from the spray-and-pray dynamics of larger funds chasing AI scale.